Mythic

Mythic Therapeutics Announces Publication of Preclinical Data Highlighting the Differentiating Properties of MYTX-011 in Molecular Cancer Therapeutics

Retrieved on: 
Tuesday, April 30, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Biopharmaceutical, Kidney, Pharmacokinetics, Neck, Half-life, Engineering, ADC, Patient, Mythic, Neoplasm, Toxicity, Paper, Head, AACR, Therapy, Cancer, NSCLC, Spacecraft, Lung cancer, Pharmaceutical industry

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced the publication of preclinical data highlighting the differentiating properties of its investigational cMET-targeting ADC, MYTX-011, in Molecular Cancer Therapeutics , a journal of the American Association for Cancer Research (AACR).

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced the publication of preclinical data highlighting the differentiating properties of its investigational cMET-targeting ADC, MYTX-011, in Molecular Cancer Therapeutics , a journal of the American Association for Cancer Research (AACR).
  • “We believe that engineering pH-dependent binding could be a particularly compelling strategy for ADCs targeting medium to low levels of cMET expression in patients.
  • A single dose of MYTX-011 showed at least three-fold higher efficacy than a benchmark ADC in mouse xenograft models of NSCLC ranging from low to high cMET expression.
  • In a repeat dose toxicology study, MYTX-011 exhibited a toxicity profile similar to other MMAE-based ADCs.

The Global AI Chips Market Report 2024-2034: Profiles of 100+ Companies Including AMD, Cerebras, d-Matrix, Etched.ai, Enfabrica, Enflame, IBM, Kneron, Neuchips, Samsung, Tenstorrent and Tiny - ResearchAndMarkets.com

Retrieved on: 
Monday, November 27, 2023
Technology, Hardware, Artificial Intelligence, Market, Artificial intelligence, Research, Investment, IBM, Field-programmable gate array, Central processing unit, Machine learning, Wigner D-matrix, Graphics processing unit, Deep learning, AMD, AI, Samsung, Modularity, Medical device, Video game, MicroATX, Mythic, Nvidia

Artificial intelligence (AI) chips are specialized microchips designed to efficiently run AI-related workloads like machine learning, neural networks, and deep learning.

Key Points: 
  • Artificial intelligence (AI) chips are specialized microchips designed to efficiently run AI-related workloads like machine learning, neural networks, and deep learning.
  • As AI technology has advanced rapidly in recent years, there has been increasing demand for hardware optimized for AI processing versus general-purpose computer chips.
  • The Global Market for AI Chips 2024-2034 provides a comprehensive analysis of the global AI chip landscape.
  • The Global Market for AI Chips 2024-2034 is ideal for semiconductor industry participants, tech investors, and companies strategizing AI chip adoption to inform planning amid this rapidly evolving space.

Global AI Chips Market Outlook Report 2024-2034, By Region, Vertical, Chip Type and 100+ Company Profiles

Retrieved on: 
Monday, November 20, 2023
Market, Artificial intelligence, Research, Investment, IBM, Machine learning, Wigner D-matrix, Deep learning, AMD, AI, Samsung, Modularity, Medical device, MicroATX, Mythic, Nvidia

DUBLIN, Nov. 20, 2023 /PRNewswire/ -- The "Global Market for AI Chips 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 20, 2023 /PRNewswire/ -- The "Global Market for AI Chips 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • As AI technology has advanced rapidly in recent years, there has been increasing demand for hardware optimized for AI processing versus general-purpose computer chips.
  • The Global Market for AI Chips 2024-2034 provides a comprehensive analysis of the global AI chip landscape.
  • The Global Market for AI Chips 2024-2034 is ideal for semiconductor industry participants, tech investors, and companies strategizing AI chip adoption to inform planning amid this rapidly evolving space.

Cartamundi and Warner Bros. Discovery Global Consumer Products Unveil the DC “Selfie Moments” Limited-Edition Hybrid Trading Cards Collection by Hro Ahead of New York Comic Con

Retrieved on: 
Wednesday, October 4, 2023
Men, Toys, Entertainment, Mobile Entertainment, Events, Concerts, Consumer, General Entertainment, Other Entertainment, Teens, Retail, Other Consumer, Women, Joker (character), Justice League, Justice, Batman/Superman/Wonder Woman: Trinity, Cheese, Mythic, Loyalty, POV, Joker, Lex Luthor, Collection, New York Comic Con, San Diego Comic-Con, The New 52, NYCC, Reward, Booster Gold, Cartamundi, Video game, Online shopping, Cryptocurrency, HRO

Discovery Global Consumer Products are proud to announce a new limited-edition collection of DC Hybrid Trading Cards by Hro: DC “Selfie Moments.” The 19-card set showcases designs that hail from DC's "The New 52" line of comic books and feature artwork from a fun series of variant covers that appear to be taken from a character's "selfie" POV!

Key Points: 
  • Discovery Global Consumer Products are proud to announce a new limited-edition collection of DC Hybrid Trading Cards by Hro: DC “Selfie Moments.” The 19-card set showcases designs that hail from DC's "The New 52" line of comic books and feature artwork from a fun series of variant covers that appear to be taken from a character's "selfie" POV!
  • The DC “Selfie Moments” limited-edition hybrid collection marks the second limited-edition hybrid collection of the year for the brand, with the first drop launching during San Diego Comic-Con in July.
  • “We are so excited to bring our newest limited-edition hybrid trading cards collection to New York Comic Con,” says John Louie, Global Head of Hro.
  • For more information on Hro and DC Hybrid Trading Cards, please visit www.hro.gg .

Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression

Retrieved on: 
Tuesday, September 26, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Cancer, Fast Track, Mythic, NSCLC, Lung cancer, Doctor of Philosophy, Patient, ADC, Massachusetts General Hospital, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, MD, MPH

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mythic’s investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression.

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mythic’s investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression.
  • This designation encompasses NSCLC patients with any level of cMET overexpression, including low and intermediate.
  • “Receiving Fast Track designation from the FDA reinforces our focus on addressing the unmet need of patients living with cMET-positive NSCLC, who currently have few effective treatments,” said Brian Fiske, PhD, Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
  • A therapeutic candidate that receives Fast Track designation may be eligible for more frequent interactions with the FDA to discuss the therapeutic candidate’s clinical trial designs and development plans.

Mythic Therapeutics to Present New Preclinical Data on MYTX-011, Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, AACR, American Association for Cancer Research, Mythic, NSCLC, Doctor of Philosophy, Cancer, Patient, ISCB Senior Scientist Award, ADC, Therapy, Pharmacology, Conference, Pharmaceutical industry

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate therapies for the treatment of a wide range of cancers, today announced that it will present new preclinical data on MYTX-011, its investigational cMET-targeting ADC, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA, from October 11-15, 2023.

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate therapies for the treatment of a wide range of cancers, today announced that it will present new preclinical data on MYTX-011, its investigational cMET-targeting ADC, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA, from October 11-15, 2023.
  • “We’re looking forward to the presentation of this preclinical data, which adds to the body of work previously presented at the American Association for Cancer Research (AACR) Annual Meeting earlier this year, demonstrating the potential of MYTX-011 to expand the utilization of ADC therapy to a broader range of patients with cMET-positive cancers, including NSCLC,” said Brian Fiske, PhD, Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
  • Presenter: Deepak Kanojia, Senior Scientist In Vivo Pharmacology, Mythic Therapeutics

Sound the Alarm! The Invasion Has Begun in Blizzard Entertainment’s Overwatch® 2

Retrieved on: 
Thursday, August 10, 2023
Entertainment, Consumer Electronics, Technology, General Entertainment, Online, Software, Electronic Games, PvP, Travel, Friends, Tracer, Rotation, Hero, Skin, Xbox Series X and Series S, Xbox One, Mythic, Creativity, Battle.net, Nintendo, Overwatch, Map, Mercy, Sojourn, Flashpoint, Steam, Tamsulosin, Video game, Food delivery, Nightclub, Gasoline, Overwatch 2

There’s something for everyone in Overwatch 2: Invasion, the latest release for Blizzard Entertainment’s cross-platform, team-based action game.

Key Points: 
  • There’s something for everyone in Overwatch 2: Invasion, the latest release for Blizzard Entertainment’s cross-platform, team-based action game.
  • Featuring all-new cinematics and hundreds of new voice lines, players can explore the start of the Overwatch 2 storyline with friends.
  • New Support hero, Illari: The 38th hero to join the game’s roster, Illari is Overwatch’s first Peruvian hero.
  • Drawing her power from the sun, her medium- and long-range abilities allow her to both heal and harm as she sees fit.

Enthusiast Gaming’s U.GG Adds World of Warcraft to its Data-Driven Community and Insights Platform

Retrieved on: 
Thursday, July 27, 2023
Associated Press v. Meltwater U.S. Holdings, Inc., Mechanics, Warcraft, RPG, MMORPG, League, EGLX, Anger, World of Warcraft, Statistics, Lich, PVP, TSX, Growth, Enthusiast Gaming, Blizzard Entertainment, Blizzard, Classic, Enthusiasm, Mythic, League of Legends, Video game, Cassette tape

U.GG’s new World of Warcraft site (u.gg/wow) provides objective, quantifiable, data-driven recommendations to help players of all levels improve their skills and mechanics via game data and statistics.

Key Points: 
  • U.GG’s new World of Warcraft site (u.gg/wow) provides objective, quantifiable, data-driven recommendations to help players of all levels improve their skills and mechanics via game data and statistics.
  • World of Warcraft is a subscription-based MMORPG released by Blizzard Entertainment in 2004 with an audience made up of a passionate and global Millennial audience.
  • The popularity of the World of Warcraft franchise has expanded with the recent launch of Wrath of the Lich King® Classic and Dragonflight™.
  • Our goal is to bring players the absolute best gaming experiences,” Shinggo Lu, Chief Product Officer at Enthusiast Gaming, said.

Cartamundi and Warner Bros. Discovery Global Consumer Products to Unveil the “Dawn of DC” Trading Card Set by Hro at San Diego Comic-Con

Retrieved on: 
Thursday, July 13, 2023
Toys, Entertainment, Professional Services, Events, Concerts, Blockchain, Books, Specialty, Apps, Applications, Technology, Retail, NFT, Licensing (Entertainment), Collection, HRO, Trinity, Superman, Batman/Superman/Wonder Woman: Trinity, Multiverse (DC Comics), Shazam, Mythic, Multimedia, News America Marketing, Marketing, Batman, Sale, Green Arrow, Wonder, Penguin, Wonder Woman, Immersion, Reward, Cryptocurrency, Cyborg, Cartamundi

Discovery Global Consumer Products are proud to announce the newest collection of DC Hybrid Trading Cards by Hro that will be unveiled at San Diego Comic-Con 2023.

Key Points: 
  • Discovery Global Consumer Products are proud to announce the newest collection of DC Hybrid Trading Cards by Hro that will be unveiled at San Diego Comic-Con 2023.
  • “At Cartamundi, we are dedicated to crafting playful products that will resonate with diverse communities,” says Tricia Bouras, Cartamundi Global Entertainment President, and CEO and President of the United States Playing Card Company of Cartamundi Entertainment.
  • “We are excited to unveil the ‘Dawn of DC’ Collection at San Diego Comic-Con, the ultimate fan experience, to debut our latest innovations,” says Masha Ievseieva, Vice President of North America Marketing and Global Insights at Cartamundi.
  • For more information on Hro and DC Hybrid NFT Trading Cards, please visit www.hro.gg .

Movellus Announces Industry-First Integrated Droop Response System for SoCs

Retrieved on: 
Tuesday, June 13, 2023
APB, TDP, DVFS, Voltage droop, Mythic, SOC, IP, VLSI, Socs, Engineering, Thumb, Silicon, Health, JTAG, DAC, Video game

SUNNYVALE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Movellus, today announced an industry-first integrated droop response system.

Key Points: 
  • SUNNYVALE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Movellus, today announced an industry-first integrated droop response system.
  • The AWM2 system adaptation time is amongst the fastest in the industry – similar in performance to full custom solutions but offered as off-the-shelf synthesizable IP.
  • “The true power of our digital IP platform is demonstrated in our new droop response system,” said Mo Faisal, CEO of Movellus, “We added autonomous, programmable behavior to our adaptive clocking solution, inserted observability functionality for silicon health and analytics, and developed a cohesive droop response solution that can be delivered as off the shelf IP.”
    The integrated droop response system combines droop detection and compensation into a complete integrated system, reducing effort while still gaining maximum benefit.
  • “Movellus' Droop Response System squeezes improvements from the voltage and frequency guardbands that we typically take for granted.